Three independent discounted-cash-flow-style models value Rigel Pharmaceuticals Inc. (New) every trading day. 0 of 3 currently price RIGL above its market price.
| Free Cash Flow model | $-105.28 |
| Excess Profit model | $-33.20 |
| Residual Earnings model | $40.84 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +22.3% |
| Net debt / EBITDA | -0.8× |
| Gross margin | +93.3% |
| Revenue CAGR | +34.8% |
| Cash conversion | 0.2× |
| Dividend yield | — |
| Buyback yield | -2.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open RIGL in StockKitty